Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease.

Recent appreciation of atherosclerosis as a chronic, inflammatory disease has rekindled efforts to examine the role that infectious agents may play in atherogenesis. In particular, much interest has focused on infection with Chlamydia pneumoniae. The possibility that a prokaryote contributes to atherogenesis has high clinical interest, as C pneumoniae infection may be a treatable risk factor. To review the evidence implicating C pneumoniae in the pathogenesis of atherosclerosis, we searched MEDLINE for articles published between January 1966 and October 2002 on the association of C pneumoniae and atherosclerosis. We also used online resources, texts, meeting abstracts, and expert opinion. We included 5 types of studies (epidemiological, pathology based, animal model, cell biology, and human antibiotic treatment trials) and extracted diagnostic, pathophysiologic, and therapeutic information from the selected literature; consensus was reached on interpretation discrepancies. Chlamydia pneumoniae is associated with atherosclerosis by epidemiological and pathology-based studies. Animal model and cell biology studies suggest that the pathogen can modulate atheroma biology, including lipid- and inflammatory-related processes. Although some preliminary antibiotic treatment trials in patients with coronary artery disease indicated a reduction in recurrent coronary events, larger studies have not shown benefits in individuals with stable coronary artery disease. It is unlikely that C pneumoniae infection is necessary to initiate atherosclerosis. Furthermore, conventional antibiotic therapy may not eradicate the organism or reduce mortality in individuals with atherosclerotic vascular disease. Nevertheless, the current body of evidence establishes this pathogen as a plausible, potentially modifiable risk factor in cardiovascular disease.

[1]  B. Horne,et al.  Serum Immunoglobulin G Antibodies to Chlamydial Heat Shock Protein 60 but Not to Human and Bacterial Homologs Are Associated With Coronary Artery Disease , 2002, Circulation.

[2]  A. Camm,et al.  Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA) , 2002, Circulation.

[3]  L. Romics,et al.  Association of Chlamydia pneumoniae With Coronary Artery Disease and Its Progression Is Dependent on the Modifying Effect of Mannose-Binding Lectin , 2002, Circulation.

[4]  I. Fong,et al.  Influence of Clarithromycin on Early Atherosclerotic Lesions after Chlamydia pneumoniae Infection in a Rabbit Model , 2002, Antimicrobial Agents and Chemotherapy.

[5]  P. Libby,et al.  Cytokines Induce Indoleamine 2,3-Dioxygenase Expression in Human Atheroma-Associated Cells: Implications for Persistent Chlamydophila pneumoniae Infection , 2002, Infection and Immunity.

[6]  U. Hoffmann,et al.  Roxithromycin Treatment Prevents Progression of Peripheral Arterial Occlusive Disease in Chlamydia pneumoniae Seropositive Men: A Randomized, Double-Blind, Placebo-Controlled Trial , 2002, Circulation.

[7]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[8]  François Mach,et al.  Influence of Helicobacter pylori Infection During Atherogenesis In Vivo in Mice , 2002, Circulation research.

[9]  G. Byrne,et al.  Chlamydia pneumoniae-infected monocytes exhibit increased adherence to human aortic endothelial cells. , 2001, Microbes and infection.

[10]  R. Peeling,et al.  Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Gutiérrez,et al.  Chlamydia pneumoniae DNA in the Arterial Wall of Patients with Peripheral Vascular Disease , 2001, Infection.

[12]  G. Hansson,et al.  Chlamydia pneumoniae Infection Does Not Induce or Modify Atherosclerosis in Mice , 2001, Circulation.

[13]  T. DeGraba,et al.  Presence of Chlamydia pneumoniae in Human Symptomatic and Asymptomatic Carotid Atherosclerotic Plaque , 2001, Stroke.

[14]  KatriinaAalto-Setälä,et al.  Chlamydia pneumoniae Does Not Increase Atherosclerosis in the Aortic Root of Apolipoprotein E–Deficient Mice , 2001 .

[15]  P. Roholl,et al.  Distribution of Chlamydia pneumoniae in the Human Arterial System and Its Relation to the Local Amount of Atherosclerosis Within the Individual , 2001, Circulation.

[16]  G. Stanek,et al.  Multicenter Comparison Trial of DNA Extraction Methods and PCR Assays for Detection of Chlamydia pneumoniae in Endarterectomy Specimens , 2001, Journal of Clinical Microbiology.

[17]  H. Katus,et al.  Chlamydia pneumoniae Infection in Circulating Human Monocytes Is Refractory to Antibiotic Treatment , 2001, Circulation.

[18]  M. Burnett,et al.  Atherosclerosis in apoE knockout mice infected with multiple pathogens. , 2001, The Journal of infectious diseases.

[19]  C. Lowenstein,et al.  Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. , 2001, The Journal of infectious diseases.

[20]  M. Sarvas,et al.  Chlamydia pneumoniae Proteins Induce Secretion of the 92-kDa Gelatinase by Human Monocyte– Derived Macrophages , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[21]  B. Horne,et al.  Prospective Study of Pathogen Burden and Risk of Myocardial Infarction or Death , 2001, Circulation.

[22]  A. Becker,et al.  Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae. , 2000, Cardiovascular research.

[23]  A. Davies,et al.  Chlamydia pneumoniae Does Not Influence Atherosclerotic Plaque Behavior in Patients With Established Carotid Artery Stenosis , 2000, Stroke.

[24]  L. Tokgözoğlu,et al.  Detection of Chlamydia pneumoniae andHelicobacter pylori DNA in Human Atherosclerotic Plaques by PCR , 2000, Journal of Clinical Microbiology.

[25]  W. Wenman,et al.  Detection of Chlamydia pneumoniae DNA in CD3+ Lymphocytes From Healthy Blood Donors and Patients With Coronary Artery Disease , 2000, Circulation.

[26]  B. Horne,et al.  Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease: Primary Clinical Results of the ACADEMIC Study , 2000, Circulation.

[27]  B. Conti,et al.  Identification of Chlamydia pneumoniae DNA in Carotid Plaques , 2000 .

[28]  PetruLiuba,et al.  Endothelial Dysfunction After Repeated Chlamydia pneumoniae Infection in Apolipoprotein E–Knockout Mice , 2000 .

[29]  Qingbo Xu,et al.  Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. , 2000, Circulation.

[30]  J. Danesh,et al.  Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. , 2000, BMJ : British Medical Journal.

[31]  J. Danesh,et al.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.

[32]  B. Coombes,et al.  Analytical Sensitivity, Reproducibility of Results, and Clinical Performance of Five PCR Assays for Detecting Chlamydia pneumoniae DNA in Peripheral Blood Mononuclear Cells , 2000, Journal of Clinical Microbiology.

[33]  J. Mehta,et al.  Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis. , 2000, Circulation.

[34]  J. Ramirez,et al.  Interactions of Chlamydia pneumoniae with human endothelial cells. , 2000, The Journal of infectious diseases.

[35]  J. Muhlestein,et al.  The ACADEMIC study in perspective (Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia). , 2000, The Journal of infectious diseases.

[36]  Indrawati,et al.  Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. , 2000, The Journal of infectious diseases.

[37]  C. Gaydos,et al.  Polymerase chain reaction detection of Chlamydia pneumoniae in circulating white blood cells. , 2000, The Journal of infectious diseases.

[38]  R. Peeling,et al.  Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results. , 2000, The Journal of infectious diseases.

[39]  R. Schmidt,et al.  Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma. , 2000, The Journal of infectious diseases.

[40]  K. Feingold,et al.  Infection and inflammation-induced proatherogenic changes of lipoproteins. , 2000, The Journal of infectious diseases.

[41]  J. Muhlestein Chlamydia pneumoniae-induced atherosclerosis in a rabbit model. , 2000, The Journal of infectious diseases.

[42]  L. Jackson Description and status of the azithromycin and coronary events study (ACES). , 2000, The Journal of infectious diseases.

[43]  M. Rosenfeld,et al.  Mouse models of C. pneumoniae infection and atherosclerosis. , 2000, The Journal of infectious diseases.

[44]  J. Lindholm,et al.  Detection of viable Chlamydia pneumoniae in abdominal aortic aneurysms. , 2000, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[45]  C. Gaydos Growth in vascular cells and cytokine production by Chlamydia pneumoniae. , 2000, The Journal of infectious diseases.

[46]  I. Fong Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis. , 2000, The Journal of infectious diseases.

[47]  H. Katus,et al.  Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction. , 2000, The Journal of infectious diseases.

[48]  M W Dunne,et al.  Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial. , 2000, The Journal of infectious diseases.

[49]  D. Margolis,et al.  Chlamydiapneumoniae Inhibits Apoptosis in Human Peripheral Blood Mononuclear Cells Through Induction of IL-101 , 2000, The Journal of Immunology.

[50]  A. Harken,et al.  Chlamydia pneumoniae activates nuclear factor kappaB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation. , 2000, The Journal of surgical research.

[51]  M. Debakey,et al.  Frequency of coexistence of cytomegalovirus and Chlamydia pneumoniae in atherosclerotic plaques. , 2000, Central European journal of public health.

[52]  H. Katus,et al.  Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. , 2000, Circulation.

[53]  Y. Chao,et al.  Infectious Agents Are Not Necessary for Murine Atherogenesis , 2000, The Journal of experimental medicine.

[54]  P. Saikku,et al.  Detection of Chlamydia pneumoniae-reactive T lymphocytes in human atherosclerotic plaques of carotid artery. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[55]  P. Apfalter,et al.  Isolation and Continuous Growth of Chlamydia pneumoniae from Arterectomy Specimens , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[56]  M. Netea,et al.  Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells , 2000, European journal of immunology.

[57]  A. Quyyumi,et al.  Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. , 2000, The American journal of cardiology.

[58]  P. Roholl,et al.  Chlamydia pneumoniae in abdominal aortic aneurysms: abundance of membrane components in the absence of heat shock protein 60 and DNA. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[59]  R. Ross Atherosclerosis is an inflammatory disease , 1999 .

[60]  F. Blasi,et al.  Chlamydia pneumoniae eradication from carotid plaques. Results of an open, randomised treatment study. , 1999, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[61]  R. Dietz,et al.  Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. , 1999, Circulation.

[62]  S. Morrison,et al.  Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. , 1999, The Journal of infectious diseases.

[63]  F. Blasi,et al.  Demonstration of Viable Chlamydia pneumoniae in Atherosclerotic Plaques of Carotid Arteries by Reverse Transcriptase Polymerase Chain Reaction , 1999, Annals of vascular surgery.

[64]  V. Tsang,et al.  Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque. , 1999, Circulation.

[65]  P. Saikku,et al.  Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms , 1999, European journal of clinical investigation.

[66]  C. Jantos,et al.  Low prevalence of Chlamydia pneumoniae in atherectomy specimens from patients with coronary heart disease. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  D. Golenbock,et al.  Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae. , 1999, Microbes and infection.

[68]  B. Horne,et al.  Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. , 1999, Circulation.

[69]  M. Mayr,et al.  Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. , 1999, Circulation.

[70]  J. Ramirez,et al.  Infection of Human Endothelial Cells with Chlamydia pneumoniae Stimulates Transendothelial Migration of Neutrophils and Monocytes , 1999, Infection and Immunity.

[71]  G. Zhong,et al.  The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. , 1999, The Journal of clinical investigation.

[72]  A. Feller,et al.  Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts. , 1999, Circulation.

[73]  G. Byrne,et al.  A Chlamydia pneumoniae Component That Induces Macrophage Foam Cell Formation Is Chlamydial Lipopolysaccharide , 1998, Infection and Immunity.

[74]  M. Shirai,et al.  Chlamydia pneumoniae in coronary and iliac arteries of Japanese patients with atherosclerotic cardiovascular diseases. , 1998, Journal of medical microbiology.

[75]  K. Dalhoff,et al.  Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease. , 1998, Atherosclerosis.

[76]  P. Libby,et al.  Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. , 1998, Circulation.

[77]  T. Quinn Does Chlamydia pneumoniae cause coronary heart disease? , 1998, Current opinion in infectious diseases.

[78]  J. Grayston,et al.  Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events. , 1998, Circulation.

[79]  M. Yacoub,et al.  Chlamydia pneumoniae in vascular tissues from heart-transplant donors , 1998, The Lancet.

[80]  G. Byrne,et al.  Induction of macrophage foam cell formation by Chlamydia pneumoniae. , 1998, The Journal of infectious diseases.

[81]  J. Carlquist,et al.  Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. , 1998, Circulation.

[82]  G. Lip,et al.  Chlamydia pneumoniae antibodies in severe essential hypertension. , 1998, Hypertension.

[83]  M. Leinonen,et al.  Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits , 1997, Infection and immunity.

[84]  I. Fong,et al.  Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. , 1997, Circulation.

[85]  R. Kinlough-Rathbone,et al.  Respiratory infection in lipid-fed rabbits enhances sudanophilia and the expression of VCAM-1. , 1997, The American journal of pathology.

[86]  J. Hughes,et al.  Preventing the emergence of antimicrobial resistance. A call for action by clinicians, public health officials, and patients. , 1997, JAMA.

[87]  J. Danesh,et al.  Chronic infections and coronary heart disease: is there a link? , 1997, The Lancet.

[88]  E. Gurfinkel,et al.  Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study , 1997, The Lancet.

[89]  A. Camm,et al.  Elevated Chlamydia pneumoniae Antibodies, Cardiovascular Events, and Azithromycin in Male Survivors of Myocardial Infarction , 1997 .

[90]  A. Lee,et al.  Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. , 1997, The Journal of infectious diseases.

[91]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[92]  G. Rodgers,et al.  Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. , 1997, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[93]  L. Campbell,et al.  Murine models of Chlamydia pneumoniae infection and atherosclerosis. , 1997, The Journal of infectious diseases.

[94]  M. Leinonen,et al.  Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. , 1997, Journal of vascular surgery.

[95]  I. Fong,et al.  Rabbit model for Chlamydia pneumoniae infection , 1997, Journal of clinical microbiology.

[96]  J. Ramírez Isolation of Chlamydia pneumoniae from the Coronary Artery of a Patient with Coronary Atherosclerosis , 1996, Annals of Internal Medicine.

[97]  M. Leinonen,et al.  Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. , 1996, Microbial pathogenesis.

[98]  R. Peeling,et al.  Chlamydiae as pathogens: new species and new issues. , 1996, Emerging infectious diseases.

[99]  M. Leinonen,et al.  Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. , 1996, Microbial pathogenesis.

[100]  M L Woods,et al.  Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. , 1996, Journal of the American College of Cardiology.

[101]  J. Ramirez,et al.  Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells , 1996, Infection and immunity.

[102]  T. Quinn,et al.  Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. , 1996, The Journal of infectious diseases.

[103]  B. Davidson,et al.  Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. , 1996, Journal of clinical pathology.

[104]  A. Coulson,et al.  Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. , 1995, Circulation.

[105]  E. O’Brien,et al.  In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae , 1995, Journal of clinical microbiology.

[106]  Y. Goo,et al.  Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[107]  M. Ward The immunobiology and immunopathology of chlamydial infections , 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[108]  W. Beatty,et al.  Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. , 1994, Microbiological reviews.

[109]  J. Tuomilehto,et al.  Importance of smoking for Chlamydia pneumoniae seropositivity. , 1994, International journal of epidemiology.

[110]  W. Dreyer,et al.  Cardiolipin-protein complexes and initiation of complement activation after coronary artery occlusion. , 1994, Circulation research.

[111]  M. Leinonen,et al.  Chlamydia pneumoniae multiplies in human endothelial cells in vitro. , 1994, Microbial pathogenesis.

[112]  H. Fukushi,et al.  Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. , 1993, The Journal of infectious diseases.

[113]  Grayston Jt Infections caused by Chlamydia pneumoniae strain TWAR. , 1992 .

[114]  D. Patton,et al.  Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. , 1992, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[115]  D. Hahn,et al.  Smoking is a potential confounder of the Chlamydia pneumoniae-coronary artery disease association. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[116]  P. Saikku,et al.  A NEW RESPIRATORY TRACT PATHOGEN: CHLAMYDIA PNEUMONIAE STRAIN TWAR , 1990, The Journal of infectious diseases.

[117]  E. Chi,et al.  Unique ultrastructure in the elementary body of Chlamydia sp. strain TWAR , 1987, Journal of bacteriology.

[118]  C. Minick,et al.  Brief Definitive Report , 2003 .

[119]  C. Frothingham THE RELATION BETWEEN ACUTE INFECTIOUS DISEASES AND ARTERIAL LESIONS , 1911 .

[120]  G. Byrne,et al.  Chlamydia Infection and Pneumonia , 2002 .

[121]  J. Danesh,et al.  Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. , 2002, European heart journal.

[122]  V. Tsang,et al.  The prevalence of Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery. , 1999, Journal of the American College of Cardiology.

[123]  V. Tsang,et al.  The prevalence of Chlamydia pneumoniaein atherosclerotic and nonatherosclerotic blood vessels of patients attending for redo and first time coronary artery bypass graft surgery , 1999 .

[124]  D. Paterson,et al.  Failure to detect Chlamydia pneumoniae in atherosclerotic plaques of Australian patients , 1998, Pathology.

[125]  S. Pavlović,et al.  Measuring of cardiolipin antibodies and plasma lipids in different stages of coronary disease. , 1993, Medicinski pregled.

[126]  J. Grayston Infections caused by Chlamydia pneumoniae strain TWAR. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[127]  H. Ziemssen,et al.  Die Aetiologie der Tuberculose , 1882 .